menu
    • menu
    [{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Myovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Mycenax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.26000000000000001,"dosageForm":"Transdermal patch","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gedeon Richter \/ Hikma","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Gedeon Richter \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Richter \/ AbbVie"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Sumitomo"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Not Applicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":null,"graph2":null,"graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":null,"companyTruncated":"Gedeon Richter \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Gedeon Richter

    Menu

    Gedeon Richter

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie, Gedeon Richter Partner on Neuropsychiatric Drug Discovery

                            Details : Companies will discover and develop novel targets for the treatment of neuropsychiatric conditions. AbbVie will have worldwide commercialization rights except for traditional markets of Richter.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $25.0 million

                            October 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Brand Name : Ryeqo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO® for Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Brand Name : Ryeqo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

                            Details : The collaboration is based on results of preclinical research carried by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years, including globally launched products such as caripraz...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 11, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed B...

                            Details : According to the agreement, Richter is responsible for the development of the denosumab, Products (to conduct both Phase 1 and Phase 3 global clinical studies) and will supply finished commercial Products for the US market.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 09, 2021

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norelgestromin,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : $263.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Richter Announces the Acquisition of Janssen’s Evra® Transdermal Contraceptive Patch Assets

                            Details : Evra is a transdermal contraceptive patch assets. The deal is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing autho...

                            Brand Name : Evra

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 03, 2020

                            Lead Product(s) : Norelgestromin,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : $263.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Mycenax Biotech

                            Deal Size : $19.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab

                            Details : Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $3.0 million

                            April 29, 2020

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Mycenax Biotech

                            Deal Size : $19.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Myovant Sciences

                            Deal Size : $80.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combinat...

                            Details : Gedeon Richter will commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, Russia, Latin America, Australia, and New Zealand.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $40.0 million

                            March 31, 2020

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Myovant Sciences

                            Deal Size : $80.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth